

Date: 29/01/2020

FREEDOM OF INFORMATION REQUEST FOI/015150 - Biologics for Crohn's Disease and Ulcerative Colitis

I have a Freedom of Information request for prescribing in Crohn's Disease and Ulcerative Colitis.

Could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Crohn's Disease and Ulcerative Colitis for each of the following treatments:

If you are unable to answer my questions with breakdown by specified conditions then please provide me with the numbers of patients treated in the last 3 months (October to December 2019 inclusive if possible) with the above drugs, regardless of disease/indication.

The figures below are for total number of patients treated with each drug for the specified timeframe.

Adalimumab [Amgevita] - 2
Adalimumab [Hulio] - 0
Adalimumab [Humira] - 27
Adalimumab [Hyrimoz] - 3 62
Adalimumab [Imraldi] - 0
Golimumab [Simponi] - 35
Infliximab [Flixabi] - 0
Infliximab [Inflectra] - 0
Infliximab [Remicade] - 2
Infliximab [Remsima] - 65
Tofacitinib [Xeljanz] - 7
Ustekinumab [Stelara] - 63
Vedolizumab [Entyvio] - 76